Most immunotherapy infusions are given every 2 to 6 weeks, depending on the specific drug and dosing schedule your oncologist selects. The total course of treatment typically lasts up to 2 years, though some patients stop sooner if the cancer responds well or side effects become difficult to manage.
Standard Infusion Schedules
The two most widely used checkpoint inhibitors each have multiple approved schedules. Pembrolizumab (Keytruda) can be given as a 200 mg infusion every 3 weeks or a larger 400 mg dose every 6 weeks. The FDA approved the 6-week option in April 2020, and it delivers the same total amount of drug over time. Nivolumab (Opdivo) follows a similar pattern: 240 mg every 2 weeks or 480 mg every 4 weeks.
Your oncologist will choose a schedule based on your cancer type, whether immunotherapy is combined with other treatments, and practical factors like how far you live from the infusion center. The less frequent options (every 4 or 6 weeks) mean fewer clinic visits without sacrificing effectiveness, which is why they’ve become increasingly popular since their approval.
What a Single Infusion Visit Looks Like
The infusion itself takes 30 to 90 minutes once the drug is prepared, depending on the medication and whether you need pre-medications to prevent reactions. But plan for your appointment to last longer than that. You’ll typically arrive early for blood work, wait for pharmacy preparation, and stay for a short observation period afterward. A full visit often runs 2 to 4 hours from check-in to checkout.
Newer subcutaneous formulations, injected under the skin rather than through an IV, are changing this. In early rollouts, subcutaneous immunotherapy takes roughly 7 minutes to administer every 4 weeks, cutting treatment time by up to 75%. In patient surveys, 64% cited the shorter clinic time as their top reason for preferring the injection over traditional IV infusion. These formulations aren’t yet available for every drug or indication, but they’re expanding rapidly.
How Long Treatment Continues
Most clinical trials tested immunotherapy for 1 to 2 years, and 2 years has become the most common planned stopping point. In practice, though, only about 20% of patients in one large study actually stopped at that mark. The rest continued indefinitely, often because both patient and oncologist felt uneasy about stopping a treatment that was working.
The evidence suggests this extra caution may not be necessary. A study of patients with advanced non-small cell lung cancer found no meaningful survival difference between those who stopped at 2 years (79% overall survival) and those who kept going (81%). These results have made oncologists more comfortable with a planned 2-year endpoint, though the decision is always individualized. Some patients stop earlier because their cancer goes into remission or because side effects outweigh the benefits. Others with more aggressive disease may stay on treatment longer.
Blood Tests and Scans Between Infusions
Immunotherapy works by unleashing your immune system against cancer cells, but that same mechanism can cause the immune system to attack healthy organs. To catch these problems early, you’ll have blood drawn before most infusion visits. The standard panel checks liver function, kidney function, thyroid hormones, and blood cell counts. Thyroid levels are typically monitored every 4 to 6 weeks during treatment, since thyroid inflammation is one of the more common side effects. Blood sugar is also tracked at each cycle because immunotherapy can, in rare cases, trigger sudden-onset diabetes.
Imaging scans to evaluate whether the treatment is shrinking your tumor are typically scheduled every 3 months. Your oncologist will compare these scans to your baseline images to assess response. Researchers at Penn Medicine have found that metabolic changes visible on imaging as early as one week after starting treatment can predict outcomes in melanoma patients, but for now, the 3-month interval remains standard practice.
What Happens If You Miss a Dose
Life doesn’t always cooperate with infusion schedules. Illness, travel, or scheduling conflicts can push an appointment back. The general approach is that short delays of a few days are rarely a problem, and your next infusion simply proceeds as planned. Longer gaps may require your care team to adjust the approach, but missing a single infusion by a week or two is unlikely to derail your treatment. If you know you’ll need to reschedule, call your oncology team early so they can advise on timing.
Factors That Change Your Schedule
Combination regimens often start with more frequent visits. When immunotherapy is paired with chemotherapy or a second immunotherapy drug, the first several cycles may require visits every 2 to 3 weeks. After the initial phase, some protocols shift to a less frequent maintenance schedule.
Side effects can also alter timing. If you develop significant immune-related inflammation in your liver, lungs, or other organs, your oncologist may pause treatment for weeks or months until the reaction resolves. These pauses are common and don’t necessarily mean treatment has failed. Many patients resume their regular schedule after the issue clears.
Your overall health and how your cancer responds will shape the schedule over time. Someone whose tumor shrinks dramatically in the first few months may have their scan intervals extended. Someone experiencing recurring side effects may switch from a 2-week to a 4-week dosing option to reduce the burden of frequent visits. The schedule you start with is rarely the exact schedule you’ll follow for the entire course of treatment.